Table 1.
Demographic and clinical characteristics of patients at baseline.
| Before PS matching | After PS matching | |||||
|---|---|---|---|---|---|---|
| Belimumab (n = 16) | Control (n = 95) | SMD | Belimumab (n = 16) | Control (n = 31) | SMD | |
| Gender, female | 14 (87.5) | 89 (93.7) | 0.213 | 14 (87.5) | 28 (90.3) | 0.090 |
| Age, years | 30.25 (11.70) | 31.40 (11.30) | 0.100 | 30.25 (11.70) | 30.94 (11.42) | 0.059 |
| Disease duration, months | 2.19 (1.22) | 2.08 (1.55) | 0.074 | 2.19 (1.22) | 2.29 (1.53) | 0.074 |
| SLEDAI‐2K score | 9.69 (3.46) | 7.57 (6.08) | 0.429 | 9.69 (3.46) | 10.00 (5.30) | 0.070 |
| PGA | 1.71 (0.57) | 1.35 (0.70) | 0.552 | 1.71 (0.57) | 1.60 (0.78) | 0.161 |
| Organ involvementa | ||||||
| Mucocutaneous | 7 (43.8) | 37 (38.9) | 0.098 | 7 (43.8) | 16 (51.6) | 0.158 |
| Musculoskeletal | 4 (25.0) | 33 (34.7) | 0.214 | 4 (25.0) | 15 (48.4) | 0.500 |
| Renal | 7 (43.8) | 32 (33.7) | 0.208 | 7 (43.8) | 14 (45.2) | 0.028 |
| Hematologic | 5 (31.2) | 28 (29.5) | 0.039 | 5 (31.2) | 9 (29.0) | 0.048 |
| Constitutional | 2 (12.5) | 16 (16.8) | 0.123 | 2 (12.5) | 8 (25.8) | 0.343 |
| Immunological | 16 (100.0) | 63 (66.3) | 1.000 | 16 (100.0) | 25 (80.6) | 0.693 |
| Vascular | 1 (6.2) | 4 (4.2) | 0.092 | 1 (6.2) | 1 (3.2) | 0.143 |
| Serositis | 1 (6.2) | 8 (8.4) | 0.083 | 1 (6.2) | 5 (16.1) | 0.317 |
| CNS | 0 (0.0) | 0 (0.0) | / | 0 (0.0) | 0 (0.0) | / |
| Blood test | ||||||
| Anti‐dsDNA positive | 15 (93.8) | 53 (68.8) | 0.674 | 15 (93.8) | 21 (70.0) | 0.648 |
| Low complement C3 | 11 (68.8) | 56 (58.9) | 0.205 | 11 (68.8) | 24 (77.4) | 0.196 |
| Low complement C4 | 10 (62.5) | 44 (46.3) | 0.329 | 10 (62.5) | 21 (67.7) | 0.110 |
| 24hUP > 0.5 g | 5 (33.3) | 19 (27.1) | 0.135 | 5 (33.3) | 10 (33.3) | <0.001 |
| Medication | ||||||
| Glucocorticoidb | 45.00 (10.17) | 37.39 (17.36) | 0.535 | 45.00 (10.17) | 42.18 (17.71) | 0.195 |
| Immunosuppressants | ||||||
| MMF | 10 (62.5) | 27 (28.4) | 0.728 | 10 (62.5) | 13 (41.9) | 0.421 |
| TAC | 1 (6.2) | 4 (4.2) | 0.092 | 1 (6.2) | 1 (3.2) | 0.143 |
| CYC | 3 (18.8) | 28 (29.5) | 0.253 | 3 (18.8) | 9 (30.0) | 0.264 |
| MTX | 1 (6.2) | 15 (15.8) | 0.308 | 1 (6.2) | 6 (19.4) | 0.400 |
| AZA | 1 (6.2) | 3 (3.2) | 0.146 | 1 (6.2) | 1 (3.2) | 0.143 |
| CsA | 0 (0.0) | 10 (10.5) | 0.485 | 0 (0.0) | 2 (6.5) | 0.371 |
Note. Data were described as mean (SD) or n (percentage).
Abbreviations: ANA, antinuclear antibody; AZA, azathioprine; CNS, central nervous system; CsA, Cyclosporin A; CYC, cyclophosphamide; dsDNA, double‐stranded DNA; MMF, mycophenolate mofetil; MTX, methotrexate; PGA, patient global assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; TAC, tacrolimus.
a
Organ involvement was based on the SLEDAI‐2K affected item.
b
The prescribed glucocorticoid dosage was converted to a prednisone equivalent dose.